Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q116032741)
Watch
English
The ‘breakthrough’ obesity drugs that have stunned researchers
scientific article published on 4 January 2023
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Crossref
retrieved
5 January 2023
title
The ‘breakthrough’ obesity drugs that have stunned researchers
(English)
1 reference
stated in
Crossref
retrieved
5 January 2023
author name string
McKenzie Prillaman
series ordinal
1
1 reference
stated in
Crossref
retrieved
5 January 2023
language of work or name
English
1 reference
stated in
Crossref
retrieved
5 January 2023
publication date
4 January 2023
1 reference
stated in
Crossref
retrieved
5 January 2023
published in
Nature
1 reference
stated in
Crossref
retrieved
5 January 2023
volume
613
1 reference
stated in
Crossref
retrieved
5 January 2023
issue
7942
1 reference
stated in
Crossref
retrieved
5 January 2023
page(s)
16-18
1 reference
stated in
Crossref
retrieved
5 January 2023
cites work
Once-Weekly Semaglutide in Adolescents with Obesity
0 references
Once-Weekly Semaglutide in Adults with Overweight or Obesity
0 references
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
0 references
Positional cloning of the mouse obese gene and its human homologue
0 references
Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut
0 references
Identifiers
DOI
10.1038/D41586-022-04505-7
1 reference
stated in
Crossref
retrieved
5 January 2023
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
